On Friday July 9, 2021, the Union for Affordable Cancer Treatment (UACT) and Knowledge Ecology International (KEI) filed joint comments with the National Institutes of Health (NIH) regarding a prospective exclusive license for a cancer therapy technology. The Federal Register notice titled, “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies” (86 FR 33326), outlined that the technology is to be licensed to Syncopation Life Sciences Inc. (Syncopation), which is based in Palo Alto, CA. The technology is an anti-CD22 CAR therapy, which has been shown to be effective inRead More →

The National Institute of Standards and Technology (NIST), a part of the US Department of Commerce, proposed a slate of detrimental changes to regulations in the Bayh-Dole Act governing “Rights to Federally Funded Inventions and Licensing of Government Owned Invention.” The public was given the opportunity to comment on the proposed changes, and by the close of the comment period on April 5, 2021 NIST had received over 81,000 comments on the issue. The proposed changes cover a variety of areas that impact policies concerning access to medicines and drug pricing, including patients’ rights to challenge the government’s grant of a taxpayer-funded invention to aRead More →

As COVID-19 continues to spread across the world, cancer patients, their doctors and families are struggling to find more information about how COVID-19 could affect them. From what is currently reported, cancer patients are a highly vulnerable group but we do not know yet how vulnerable. We know that cancer and cancer treatments can weaken a patient’s immune systems but there are not many data points, nor test results yet. What is most needed today is collaboration and openness. UACT signed this Open Letter to the World Health Organization (WHO) and its Member States on the proposal by Costa Rica to create a global poolRead More →

DATE: Thursday May 9, 2019 RE: Civil Society Open Letter Regarding Harmful Changes to WHA Transparency Resolution 9 May 2019 – Today more than 100 civil society organizations and health experts sent an open letter to World Health Organization (WHO) Member State delegates urging them to oppose harmful proposed changes to the draft World Health Assembly (WHA) resolution on transparency to be discussed at the 72nd WHA on May 20-28, 2019 in Geneva, Switzerland. The groups and individuals signing the open letter said they were appalled at proposals put forth at informal negotiations at the WHO on Tuesday May 7, 2019, which, “would make thisRead More →

On Wednesday December 5, 2018, UACT, along with KEI, Social Security Works, Health GAP, Public Citizen, Dr. Ophira Ginsburg, and James Love, submitted joint comments in response to a proposed exclusive license for patents on CAR T technology for the treatment of cancers. The Federal Register notice (83 FR 58262) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Cancers,” outlined the National Institutes of Health’s intent to grant an exclusive license on these technologies to ElevateBio, a company whose leadership includes the investors behind recent budget-breaking treatments,Read More →